Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma

Liver International

Volumn 31, Issue 1, 2011, Pages 120-131

  Yorita, Kenji ^a   Takahashi, Nobuyasu ^a   Takai, Hirotake ^b   Kato, Atsuhiko ^b   Suzuki, Masami ^b   Ishiguro, Takahiro ^b   Ohtomo, Toshihiko ^b   Nagaike, Koki ^a   Kondo, Kazuhiro ^a   Chijiiwa, Kazuo ^a   Kataoka, Hiroaki ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Glypican 3; Hepatocellular carcinoma; Immunohistochemistry; Prognosis

Indexed keywords

GLYPICAN 3; MESSENGER RNA; MONOCLONAL ANTIBODY;

ADULT; ANTIGEN RETRIEVAL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; FEMALE; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BIOPSY; CARCINOMA, HEPATOCELLULAR; CELL MEMBRANE; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GLYPICANS; HEPACIVIRUS; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78650123226     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02359.x     Document Type: Article

References (23)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
2. Thomas MB, Abbruzzese JL. Opportunities for targeted therapies in hepatocellular carcinoma. J Clin Oncol 2005; 23: 8093-108.
3. Jakubovic BD, Jothy S. Glypican-3: from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol 2007; 82: 184-9.
4. Filmus J, Capurro M, Rast J. Glypicans. Genome Biol 2008; 9: 224.
5. Lage H, Dietel M. Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5. Gene 1997; 188: 151-6.
6. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res 1997; 57: 5179-84.
7. Kandil DH, Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol 2009; 16: 125-9.
8. Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
9. Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol 2006; 30: 1405-11.
10. Wang XY, Degos F, Dubois S, et al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol 2006; 37: 1435-41.
11. Wang HL, Anatelli F, Zhai QJ, et al. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med 2008; 132: 1723-8.
12. Shirakawa H, Suzuki H, Shimomura M, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 1403-7.
13. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med 2005; 37: 360-3.
14. Takai H, Kato A, Ishiguro T, et al. Optimization of tissue processing for immunohistochemistry for the detection of human glypican-3. Acta Histochem 2010; 112: 240-50.
15. Ishiguro T, Sugimoto M, Kinoshita Y, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 2008; 68: 9832-8.
16. Nakano K, Orita T, Nezu J, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun 2009; 378: 279-84.
17. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009; 51: 810-20.
18. Liu B, Paranjpe S, Bowen WC, et al. Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation. Am J Pathol 2009; 175: 717-24.
19. Morford LA, Davis C, Jin L, et al. The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2. Hepatology 2007; 46: 1541-7.
20. Zittermann SI, Capurro MI, Shi W, Filmus J. Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo. Int J Cancer 2010; 126: 1291-301.
21. Lai JP, Sandhu DS, Yu C, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008; 47: 1211-22.
22. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-54.
23. Takai H, Kato A, Kato C, et al. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int 2009; 29: 1056-64.